It has been demonstrated that HIV-1 gp120 resembles several important properties of immunoglobulins allowing it strong influence on the human immune system, especially through induction of the deceptive imprinting and deregulation of the immune network. On the other hand there are many unanswered questions concerning properties and control of the genetically modified viruses and bacteria used as vectors in AIDS vaccines. This situation opens a serious question about the safety of vectored AIDS vaccine and the ethics of their trials in humans
The safety of attenuated poxviruses in HIV-1-infected individuals is an important consideration in t...
Live recombinant vectors entered the AIDS vaccine field with the realization that live attenuated HI...
Abstract The development of an efficient prophylactic HIV vaccine has been one of the major challeng...
The latest generation of lentiviral vectors based on HIV-1 is one of the most efficient tools for ge...
Clinical trials of candidate HIV vaccines pose virtually all of the problems possible in vaccine tri...
In the first AIDS vaccine trial, immunizing preparations were based on HIV-1 Env protein (gp160). Im...
The goal of a prophylactic human immunodeficiency (HIV) vaccine is to elicit immune response(s) that...
Human immunodeficiency virus (HIV) has infected 50 million people worldwide and killed 16 million so...
Trial Design: HIV-1 vaccine development has advanced slowly due to viral antigenic diversity, poor i...
A phase 1 trial of a candidate human immunodeficiency virus type 1 (HIV-I) vaccine was done in 25 he...
HIV-1 vaccine development has advanced slowly due to viral antigenic diversity, poor immunogenicity ...
TRIAL DESIGN: HIV-1 vaccine development has advanced slowly due to viral antigenic diversity, poor i...
Expectations of a vaccine to prevent acquired immunodeficiency syndrome (AIDS) are rising. Not only ...
A broad range of structural, functional, and immunological similarities between HIV-1 gp120 and huma...
Development of an effective AIDS vaccine is a global priority. However, the extreme diversity of HIV...
The safety of attenuated poxviruses in HIV-1-infected individuals is an important consideration in t...
Live recombinant vectors entered the AIDS vaccine field with the realization that live attenuated HI...
Abstract The development of an efficient prophylactic HIV vaccine has been one of the major challeng...
The latest generation of lentiviral vectors based on HIV-1 is one of the most efficient tools for ge...
Clinical trials of candidate HIV vaccines pose virtually all of the problems possible in vaccine tri...
In the first AIDS vaccine trial, immunizing preparations were based on HIV-1 Env protein (gp160). Im...
The goal of a prophylactic human immunodeficiency (HIV) vaccine is to elicit immune response(s) that...
Human immunodeficiency virus (HIV) has infected 50 million people worldwide and killed 16 million so...
Trial Design: HIV-1 vaccine development has advanced slowly due to viral antigenic diversity, poor i...
A phase 1 trial of a candidate human immunodeficiency virus type 1 (HIV-I) vaccine was done in 25 he...
HIV-1 vaccine development has advanced slowly due to viral antigenic diversity, poor immunogenicity ...
TRIAL DESIGN: HIV-1 vaccine development has advanced slowly due to viral antigenic diversity, poor i...
Expectations of a vaccine to prevent acquired immunodeficiency syndrome (AIDS) are rising. Not only ...
A broad range of structural, functional, and immunological similarities between HIV-1 gp120 and huma...
Development of an effective AIDS vaccine is a global priority. However, the extreme diversity of HIV...
The safety of attenuated poxviruses in HIV-1-infected individuals is an important consideration in t...
Live recombinant vectors entered the AIDS vaccine field with the realization that live attenuated HI...
Abstract The development of an efficient prophylactic HIV vaccine has been one of the major challeng...